Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors

Thelma S. Angeles, Robert L. Hudkins(State Street (United States))

Expert Opinion on Drug Discovery

October 5, 2016

10.1080/17460441.2016.1245286

Cited by 113

Related Papers

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

|ACS Chemical Neuroscience|2011|436

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

|PubMed|2003|124

Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives

|Journal of Medicinal Chemistry|1997|120

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

|Molecular Cancer Therapeutics|2007|112

Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells

|Blood|2005|105